目的 通過(guò)構(gòu)建注射用英夫利西單抗的藥物利用評(píng)價(jià)（DUE）標(biāo)準(zhǔn)，促進(jìn)注射用英夫利西單抗的臨床合理應(yīng)用。方法 使用屬性層次模型（AHM）結(jié)合逼近理想解排序（TOPSIS）法，對(duì)安徽醫(yī)科大學(xué)附屬宿州醫(yī)院2023年1月—2024年12月共197例患者的注射用英夫利西單抗臨床使用情況進(jìn)行合理性評(píng)價(jià)。結(jié)果 評(píng)價(jià)的197例病例中，完全合理的有16例，占比8.12%；合理的有54例，占比27.41%；基本合理的有99例，占比50.25%；不合理的有28例，占比14.21%。結(jié)論 安徽醫(yī)科大學(xué)附屬宿州醫(yī)院注射用英夫利西單抗的臨床應(yīng)用基本合理，但在適應(yīng)證、輸液反應(yīng)及處理、病程記錄、禁忌證、注意事項(xiàng)、不良反應(yīng)處理及監(jiān)測(cè)等方面存在較高的不合理率。建立的英夫利西單抗的DUE標(biāo)準(zhǔn)，可用于臨床合理用藥的評(píng)價(jià)。

Objective To promote the rational clinical use of Infliximab for injection by establishing the DUE criteria for Infliximab for injection. Methods AHM combined with TOPSIS method was used to evaluate the rationality of Infliximab for injection in 197 patients in Suzhou Hospital Affiliated to Anhui Medical University from January 2023 to December 2024. Results Among 197 cases evaluated, 16 cases were completely reasonable, accounting for 8.12%, 54 cases were reasonable, accounting for 27.41%, 99 cases were basically reasonable, accounting for 50.25%. There were 28 cases of unreasonable, accounting for 14.21%. Conclusion The clinical application of Infliximab for injection in Suzhou Hospital Affiliated to Anhui Medical University is basically reasonable, but there are high unreasonable rates in indications, infusion reactions and treatment, course records, contraindications, precautions, treatment and monitoring of adverse reactions. The established DUE criteria for Infliximab for injection can be used to evaluate the rational use of infliximab in clinical practice.

R979.5

安徽省臨床醫(yī)學(xué)研究轉(zhuǎn)化專(zhuān)項(xiàng)項(xiàng)目（202304295107020119）